<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:mp ids='MP_0009308'>Adenocarcinoma</z:mp> of the esophagus is generally attributed to the <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> of intestinal metaplastic lesions (<z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>) </plain></SENT>
<SENT sid="1" pm="."><plain>On the basis of our preliminary data that showed significant acidic fibroblast growth factor <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus, we studied expression of fibroblast growth factor in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and its precursor lesions, <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>, low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Fibroblast growth factor belongs to a family of <z:chebi fb="1" ids="15841">polypeptides</z:chebi> that are involved in differentiation and cellular proliferation </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We examined 30 esophagectomy specimens that were resected for <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (n = 27) and high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 3) </plain></SENT>
<SENT sid="4" pm="."><plain>After confirmation of the diagnosis by routine light microscopy, the index lesions (invasive <z:mp ids='MP_0002038'>carcinomas</z:mp>) and adjoining Barrett's mucosa were evaluated with a monoclonal antibody against human acidic fibroblast growth factor </plain></SENT>
<SENT sid="5" pm="."><plain>The results are expressed with the use of an immunoreactive score that allows distinction between weak, moderate, and strong immunoreactivity </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:mp ids='MP_0009308'>Adenocarcinoma</z:mp> demonstrated a moderate-to-strong mean immunoreactive score of 8 </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> demonstrated a weak-to-moderate mean score of 4.5, which was significantly different (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_167'>Intestinal metaplasia</z:mpath> and low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> displayed even weaker expression of fibroblast growth factor, with a negligible immunoreactive score less than 1 (p &lt; 0.005) </plain></SENT>
<SENT sid="9" pm="."><plain>Seventy-five percent of evaluable cases demonstrated an increasing degree of fibroblast growth factor expression in the spectrum of lesions ranging from <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data indicate that in patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising in association with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, fibroblast growth factor is generally sequentially accumulated in the progression from <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>This progression may affect future investigation into the role of fibroblast growth factors in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and, possibly, the application of fibroblast growth factor immunohistochemistry to diagnosis </plain></SENT>
</text></document>